RT Journal Article
SR Electronic
T1 Effects of a novel infant formula on weight gain and body composition of infants: The INNOVA 2020 study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.27.22281417
DO 10.1101/2022.10.27.22281417
A1 Plaza-Diaz, Julio
A1 Ruiz-Ojeda, Francisco Javier
A1 Morales, Javier
A1 de la Torre, Ana Isabel Cristina
A1 García-García, Antonio
A1 Nuñez de Prado, Carlos
A1 Coronel, Cristóbal
A1 Crespo, Cyntia
A1 Ortega, Eduardo
A1 Marín-Pérez, Esther
A1 Ferrerira, Fernando
A1 García-Ron, Gema
A1 Galicia, Ignacio
A1 Santos-García-Cuéllar, María Teresa
A1 Moroto, Marcos
A1 Ruiz, Paola
A1 Martín, Raquel
A1 Viver-Gómez, Susana
A1 Gil, Angel
YR 2022
UL http://medrxiv.org/content/early/2022/11/14/2022.10.27.22281417.abstract
AB Background Breastmilk is the most appropriate food for infants and exclusive breastfeeding is highly recommended for the first six months of life to promote adequate growth and development and lower infant morbidity and mortality. Among the best-documented benefits of breastfeeding is the reduced risk of disease and infections such as pneumonia, diarrhea and acute otitis media. Nonetheless, there are situations in which the infant cannot be breastfed; therefore, it is essential to use an appropriately designed infant formula. As current infant formulas incorporate novel ingredients to partly mimic the composition of human milk, the safety and suitability of each specific infant formula should be tested by clinical evaluation in the target population. Here, we report the results of a multicenter, randomized, blinded, controlled clinical trial that aimed to evaluate a novel starting formula on weight gain and body composition of infants up to 6 and 12 months (INNOVA 2020 study), as well as safety and tolerability. The complete protocol of this study has been previously issued.Study design 210 infants (70/group) were enrolled in the study, and completed the intervention until 12 months of age. For the intervention period, infants were divided into three groups: group 1 received the formula 1 (Nutribén® Innova1 or INN), with a lower amount of protein, and enriched in α-lactalbumin protein, and with a double amount of docosahexaenoic acid (DHA)/ arachidonic acid (ARA) than the standard formula; it also contained a thermally inactivated postbiotic (Bifidobacterium animalis subsp. lactis, BPL1™ HT). Group 2 received the standard formula or formula 2 (Nutriben® Natal or STD) and the third group was exclusively breastfed for exploratory analysis and used as a reference (BFD group). During the study, visits were made at 21 days, 2, 4, 6, and 12 months of age, with ± 3 days for the visit at 21 days of age, ± 1 week for the visit at 2 months, and ± 2 weeks for the others. During the first 6 months of the study, the infants were only supplied with the starting formula or natural breastfeeding.Results The primary outcome, weight gain, was higher in both formula groups than in the BFD group at 6 and 12 months, whereas no differences were found between STD and INN groups neither at 6 nor at 12 months. Likewise, BMI was higher in infants fed the two formulas compared with the BFD group. Regarding body composition, length, head circumference and tricipital/subscapular skinfolds were alike between groups. The INN formula was considered safe as weight gain and body composition were within the normal limits, according to WHO standards. The BFD group exhibited more liquid consistency in the stools compared to both formula groups. All groups showed similar digestive tolerance and infant behavior. However, a higher frequency of gastrointestinal (GI) symptoms was reported by the STD formula group (291), followed by the INN formula (282) and the BFD groups (227). There were fewer respiratory, thoracic, and mediastinal disorders among BFD children. Additionally, infants receiving the INN formula experienced significantly fewer general disorders and disturbances than those receiving the STD formula. Indeed, atopic dermatitis, bronchitis, and bronchiolitis were significantly more prevalent among infants who were fed the STD formula compared to those fed INN formula or breastfed. To evaluate whether there are significant differences between formula treatments, beyond growth parameters, it would seem necessary to examine more precise health biomarkers and to carry out long-term longitudinal studies.Clinical Trial Registration The trial was registered with Clinicaltrial.gov (NCT05303077) on March 31, 2022, and lastly updated on April 7, 2022.Competing Interest StatementThe present study was funded by Alter Farmacia S. A. The funding sponsor had no role in the design of the study, the collection, analysis, or interpretation of the data, and the writing of the manuscript. Javier Morales is employee at Alter Farmacia S. A. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Clinical TrialNCT05303077Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT05303077 Funding StatementThe present study was funded by Alter Farmacia S. A. The funding sponsor had no role in the design of the study, the collection, analysis, or interpretation of the data, and the writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This clinical trial was carried out following the recommendations of the International Conference on Harmonization Tripartite on PCBs, the ethical-legal principles established in the latest revision of the Declaration of Helsinki, as well as the current regional regulations that regulate pharmacovigilance and food safety. The present study was approved by the Committee for Technical Investigation in Regional Medicine in the Madrid Community (CEIm-R) dated 11/05/2018 under the name INNOVA2020 version 2.0. All personal data obtained in this study are confidential. They were treated under the Spanish Organic Law 3/2018, of December 5, on the Protection of Personal Data and guarantee of digital rights. The researchers or the institutions implicated in the study allowed direct access to the data or source documents for monitoring, auditing, and review by the CEIm-R. They also allowed inspection of the trial by the health authorities.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors